Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), achieved its primary endpoint by demonstrating a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback